Intraocular Pressure and Ocular Perfusion Pressure of Cosopt in Normal Tension Glaucoma
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
To prove the non-inferiority of the fixed timolol-dorzolamide combination (Cosopt) compared
to 0.005% latanoprost (Xalatan) in the aspects of intraocular pressure (IOP) and ocular
perfusion pressure (OPP) in subjects with normal tension glaucoma (NTG)
Clinical hypotheses. Primary hypothesis
- Cosopt group is non-inferior to Xalatan group in diurnal IOP reduction.
Secondary hypothesis
- Cosopt group is non-inferior to Xalatan group in diurnal diastolic and systolic OPP.